Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results

作者: H. BALLENTINE CARTER , PATRICK C. WALSH , PATRICIA LANDIS , JONATHAN I. EPSTEIN

DOI: 10.1016/S0022-5347(05)65271-8

关键词: Rectal examinationProstatectomyBiopsyProstate-specific antigenProstateProstate cancerUrologySurgeryMedicineStage (cooking)Cancer

摘要: Purpose: We evaluate a strategy of expectant management for men with stage T1c prostate cancer.Materials and Methods: A total 81 (median age 65 years, range 52 to 72) cancer who were thought have small volume based on needle biopsy findings specific antigen (PSA) density followed more than 1 year semiannual PSA digital rectal examination, annual biopsies followup 23 months, 12 58). recommendation treatment was made if disease progression indicated by unfavorable (Gleason pattern 4 or 5, greater 2 cores cancer, 50% involvement any core cancer). Curable defined pathological examination radical prostatectomy specimens as 1) organ confined Gleason score 7 less, 2) extraprostatic extension (3+4) less negative margins, seminal vesicles lymph nodes, or...

参考文章(6)
H. Ballentine Carter, Jurga Sauvageot, Patrick C. Walsh, Jonathan I. Epstein, Prospective evaluation of men with stage T1c adenocarcinoma of the prostate The Journal of Urology. ,vol. 157, pp. 2206- 2209 ,(1997) , 10.1016/S0022-5347(01)64719-0
Peter A. Humphrey, David W. Keetch, Deborah S. Smith, David L. Shepherd, William J. Catalona, Prospective characterization of pathological features of Prostatic Carcinomas Detected Via Serum Prostate Specific Antigen Based Screening The Journal of Urology. ,vol. 155, pp. 816- 820 ,(1996) , 10.1016/S0022-5347(01)66316-X
Jonathan I. Epstein, Pathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable (Stage T1 c) Prostate Cancer JAMA: The Journal of the American Medical Association. ,vol. 271, pp. 368- 374 ,(1994) , 10.1001/JAMA.1994.03510290050036
Jonathan I Epstein, Patrick C Walsh, H.Ballentine Carter, Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology. ,vol. 57, pp. 1112- 1116 ,(2001) , 10.1016/S0090-4295(01)00979-7